PREGNANCY AND BIRTH IN A PATIENT WITH WEGNER'S DISEASE (CLINICAL CASE)
Main Article Content
Abstract
Granulomatosis with polyangiitis (GPA, Wegener's disease) is a rare, potentially life-threatening systemic vasculitis with autoimmune pathogenesis characterized by necrotizing granulomatous inflammation and damage to small and medium-sized vessels, primarily in the upper and lower respiratory tract and kidneys. Pregnancy in the background of GPA is a unique and extremely complex clinical situation, which poses a complex of interrelated tasks for rheumatologists, obstetricians-gynecologists and neonatologists: control of the activity of vasculitis, minimization of risks for the development of the fetus, associated both with the disease itself and with aggressive pharmacotherapy, and ensuring the safety of the mother. Description and analysis of a clinical case of pregnancy in a patient with granulomatosis with polyangiitis is relevant both from a scientific and practical point of view. This allows us to summarize the complex experience of interdisciplinary interaction and evaluate the effectiveness and safety of the therapeutic methods used strategies and contribute to the development of future clinical guidelines for this vulnerable patient population.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
1. Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023; 37(10): 2016-2027. doi: 10.1111/jdv.19236
2. McCombe CL, Wegner A, Wirtz L, Zamora CS, Casanova F, Aditya S, et al. Plant pathogenic fungi hijack phosphate signaling with conserved enzymatic effectors. Science. 2025; 387(6737): 955-962. doi: 10.1126/science.adl5764
3. Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, et al. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. JAMA Dermatol. 2024; 160(9): 953-963. doi: 10.1001/jamadermatol.2024.2463
4. Chhetri RCK, Gole S, Mallari AJP, Dutta A, Zahra F. An Unusual Case of Dilated Cardiomyopathy in Wegner's Granulomatosis. Cureus. 2022; 14(6): e25975. doi: 10.7759/cureus.25975
5. Kozycki CT, Kodati S, Huryn L, Wang H, Warner BM, Jani P, et al. Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome. Ann Rheum Dis. 2022; 81(10): 1453-1464. doi: 10.1136/annrheumdis-2022-222629
6. Jeffries L, Mis EK, McWalter K, Donkervoort S, Brodsky NN, Carpier JM, et al. Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. Genet Med. 2024; 26(2): 101023. doi: 10.1016/j.gim.2023.101023
5. Morleo M, Venditti R, Theodorou E, Briere LC, Rosello M, Tirozzi A, et al. De novo missense variants in phosphatidylinositol kinase PIP5KIγ underlie a neurodevelopmental syndrome associated with altered phosphoinositide signaling. Am J Hum Genet. 2023; 110(8): 1377-1393. doi: 10.1016/j.ajhg.2023.06.012
8. Xie R, Fan D, Cheng X, Yin Y, Li H, Wegner SV, et al. Living therapeutics: Precision diagnosis and therapy with engineered bacteria. Biomaterials. 2025; 321: 123342. doi: 10.1016/j.biomaterials.2025.123342